178 related articles for article (PubMed ID: 33024933)
1. Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy.
Baumann D; Offringa R
Cell Stress; 2020 Aug; 4(10):248-251. PubMed ID: 33024933
[TBL] [Abstract][Full Text] [Related]
2. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.
Baumann D; Hägele T; Mochayedi J; Drebant J; Vent C; Blobner S; Noll JH; Nickel I; Schumacher C; Boos SL; Daniel AS; Wendler S; Volkmar M; Strobel O; Offringa R
Nat Commun; 2020 May; 11(1):2176. PubMed ID: 32358491
[TBL] [Abstract][Full Text] [Related]
3. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
5. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.
Li T; Liu T; Zhu W; Xie S; Zhao Z; Feng B; Guo H; Yang R
Clin Med Insights Oncol; 2021; 15():11795549211035540. PubMed ID: 34408525
[TBL] [Abstract][Full Text] [Related]
6. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
De Wispelaere W; Annibali D; Tuyaerts S; Lambrechts D; Amant F
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922556
[TBL] [Abstract][Full Text] [Related]
8. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
10. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
Deng H; Zhang Z
J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment.
Yoo SY; Badrinath N; Jeong SN; Woo HY; Heo J
Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32575351
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment.
Jeon Y; Kang H; Yang Y; Park D; Choi B; Kim J; Kim J; Nam K
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230744
[TBL] [Abstract][Full Text] [Related]
14. Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade.
Liu X; Feng Y; Xu J; Shi Y; Yang J; Zhang R; Song J; Bai X; Wu X; Bao Y; Luo Y; Li H; Chai L; Gong C; Wang Y; Chen B; Hu J; Fu Y; Luo Y; Zhang H; Shi H
J Control Release; 2021 Apr; 332():194-209. PubMed ID: 33631225
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer resistance mechanisms: challenges to immunotherapy.
Hanna A; Balko JM
Breast Cancer Res Treat; 2021 Nov; 190(1):5-17. PubMed ID: 34322780
[TBL] [Abstract][Full Text] [Related]
16. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
17. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
[TBL] [Abstract][Full Text] [Related]
18. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
19. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
[TBL] [Abstract][Full Text] [Related]
20. Immune suppression and reversal of the suppressive tumor microenvironment.
Shimizu K; Iyoda T; Okada M; Yamasaki S; Fujii SI
Int Immunol; 2018 Sep; 30(10):445-454. PubMed ID: 29939325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]